Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Contineum Therapeutics, Inc. - Common stock (CTNM)
Company Research
Source: Yahoo! Finance
-Successful completion of Initial Public Offering with strong syndicate of existing and new investors- SAN DIEGO, May 16, 2024 BUSINESS WIRE )--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of NI&I indications, today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress. "2024 has been a pivotal year of growth for Contineum, as we transitioned to a publicly traded company, expanded the development of PIPE-791 into fibrotic diseases, and nominated our third internally derived development candidate," said Carmine Stengone, Contineum's Chief Executive Officer. "We have an exciting year ahead of us focused on clinical execution – we have initiated a Phase 2 trial of PIPE-307 in relapse-remitting multiple sclerosis (R
Show less
Read more
Impact Snapshot
Event Time:
CTNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTNM alerts
High impacting Contineum Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CTNM
News
- Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of DirectorsBusiness Wire
- Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare ConferenceBusiness Wire
- Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate SecretaryBusiness Wire
- Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of DirectorsBusiness Wire
- Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire
CTNM
Sec Filings
- 6/24/24 - Form 4
- 6/24/24 - Form 3
- 6/24/24 - Form 8-K
- CTNM's page on the SEC website